Although immune checkpoint inhibitors have improved cancer outcomes, their use can trigger autoimmune toxicities affecting essentially any organ system. In the cardiovascular system, these immune-related adverse events can manifest as myocarditis, pericarditis, accelerated atherosclerosis, vasculitis, arrhythmias, and...
Kerry L. Reynolds, A.-C. Villani, Z. Drobni et al.· JACC CardioOncology· 0 citations
BACKGROUND
The use of multiagent immunosuppressive therapy (IST) to treat immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) increases the risk of infection. Time-normalized infection rates in a large cohort have not been previously reported. Predictors of opportunistic and nonopportunistic...
Ross D. Merkin, T. Lim, D. Restifo et al.· The Journal of the National...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.